Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsHAP CareSource Sunlenca Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentHap Caresource Mi Coordinated HealthPolicy N/A

    Human Immunodeficiency Virus - Sunlenca Prior Authorization Policy

    Customize your policy alerts

    Sign up for all hap_caresource_mi_coordinated_health policy alerts

    Know when hap_caresource_mi_coordinated_health releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Medical benefit prior authorization and dosing approval for Sunlenca (lenacapavir subcutaneous injection) used with an optimized antiretroviral background regimen in adults with multidrug-resistant HIV-1.

    Policy Summary
    PayerHap Caresource Mi Coordinated Health
    PolicyHuman Immunodeficiency Virus - Sunlenca Prior Authorization Policy
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Last ReviewJan 7, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization for medical benefit coverage of Sunlenca and document that the patient meets the applicable authorization and dosing criteria.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    18+Minimum age for initial therapy
    3 of 4Antiretroviral classes with resistance required
    927 mgSubcutaneous injection dose
    Every 6 monthsMaintenance injection frequency

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    6 months
    Initial approval duration
    1 yearContinuation approval duration

    Recommended Authorization Criteria

    Initial Therapy

    Approve for 6 months when all initial therapy criteria are met.

    Initial Therapy: The patient is at least 18 years of age; according to the prescriber, is failing a current antiretroviral regimen for HIV; according to the prescriber, has resistance to two or more agents from at least three of the following four antiviral classes: nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, and integrase strand transfer inhibitors; will take Sunlenca in combination with an optimized antiviral background regimen including one or more other antiretroviral agents; and Sunlenca is prescribed by or in consultation with a physician who specializes in the treatment of HIV infection.Age ≥ 18 years; resistance to ≥2 agents from ≥3 of 4 classes

    Continuation Therapy

    Approve for 1 year when all continuation therapy criteria are met.

    Currently Receiving Sunlenca: The medication will continue to be taken in combination with an optimized antiviral background regimen including one or more other antiretroviral agents, and the patient has responded to a Sunlenca-containing regimen, as determined by the prescriber.Examples of response include HIV RNA <50 copies/mm³, HIV-1 RNA reduction ≥0.5 log10 from baseline in viral load, or improvement or stabilization of CD4 T-cell count

    Dosing

    Approve the established dosing. Requests for dosing outside the established regimen require case-by-case clinical review.

    Established Dosing: Administer an initial dose of 927 mg subcutaneously one time, followed by a maintenance dose of 927 mg subcutaneously every 6 months.Maintenance dose every 6 months, ±2 weeks from the date of the last injection

    Dosing exceptions are reviewed case by case by a Medical Director or Pharmacist.

    Sunlenca is not recommended for HIV pre-exposure prophylaxis (PrEP). Sunlenca is not approved for this indication.

    Sunlenca is not recommended for treatment-naive patients with HIV. Sunlenca is not approved for this indication.

    Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. The criteria may be updated as new published data become available.

    Authorization and Documentation Requirements

    Prior Authorization

    Prior Authorization Required

    Submit prior authorization for medical benefit coverage of Sunlenca. Approval is recommended only when the applicable authorization criteria and dosing requirements are met; extended approval is allowed when the patient continues to meet them.

    • All approvals are issued for the duration specified in the applicable criteria.
    • One month of authorization equals 30 days.
    Documentation Required

    HIV Specialist Involvement

    Sunlenca must be prescribed by, or used in consultation with, a physician who specializes in treating HIV infection because of the specialized evaluation, diagnosis, monitoring, and long-term efficacy requirements.

    • Document the HIV specialist prescriber or consultant in the authorization request.

    Therapy Overview

    Sunlenca (lenacapavir) is an HIV-1 capsid inhibitor indicated in combination with other antiretroviral agents for heavily treatment-experienced adults with multidrug-resistant HIV-1 who are failing their current regimen because of resistance, intolerance, or safety considerations. Treatment is intended to achieve viral resuppression when possible, or otherwise minimize viral load and support CD4 T-cell status. Sunlenca tablets are also available, but the tablets themselves are not addressed by this policy.

    Initial Therapy

    Initial Therapy

    Approve for 6 months if all initial therapy criteria are met.

    Initial Therapy: The patient is at least 18 years of age; according to the prescriber, is failing a current antiretroviral regimen for HIV; according to the prescriber, has resistance to two or more agents from at least three of the following four antiviral classes: nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, and integrase strand transfer inhibitors; will take Sunlenca in combination with an optimized antiviral background regimen including one or more other antiretroviral agents; and Sunlenca is prescribed by or in consultation with a physician who specializes in the treatment of HIV infection.Age ≥ 18 years; resistance to ≥2 agents from ≥3 of 4 classes

    Continuation Therapy

    Currently Receiving Sunlenca

    Approve for 1 year if both continuation therapy criteria are met.

    Currently Receiving Sunlenca: The medication will continue to be taken in combination with an optimized antiviral background regimen including one or more other antiretroviral agents, and the patient has responded to a Sunlenca-containing regimen, as determined by the prescriber.Examples of response include HIV RNA <50 copies/mm³, HIV-1 RNA reduction ≥0.5 log10 from baseline in viral load, or improvement or stabilization of CD4 T-cell count

    Dose and Frequency

    Sunlenca dosing
    Initial dose927 mg subcutaneously once
    Maintenance dose927 mg subcutaneously every 6 months
    Maintenance timing windowPlus or minus 2 weeks from the date of the last injection

    Administration Setting

    Note

    Administer injections in the office

    Sunlenca subcutaneous injections are administered by a healthcare provider in the office.

    Policy Summary
    PayerHap Caresource Mi Coordinated Health
    PolicyHuman Immunodeficiency Virus - Sunlenca Prior Authorization Policy
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Last ReviewJan 7, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization for medical benefit coverage of Sunlenca and document that the patient meets the applicable authorization and dosing criteria.
    SourceLink
    On This Page
    Recommended Authorization CriteriaAuthorization and Documentation RequirementsTherapy OverviewInitial TherapyContinuation TherapyDose and FrequencyAdministration Setting
    Documentation Required

    Clinical Eligibility Information

    Document whether the request is for initial therapy or continuation therapy and include the clinical information supporting eligibility. For initial therapy, document that the patient is at least 18 years old, is failing the current antiretroviral regimen, has resistance to two or more agents from at least three antiviral classes, and will receive Sunlenca with an optimized background regimen containing one or more other antiretroviral agents. For continuation therapy, document ongoing use with an optimized background regimen and response to a Sunlenca-containing regimen.

    • Resistance must involve at least two agents from at least three of these classes: nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, and integrase strand transfer inhibitors.
    • Examples of documented response include HIV RNA < 50 copies/mm³, an HIV-1 RNA reduction of at least 0.5 log10 from baseline viral load, or improvement or stabilization of the CD4 T-cell count.
    • Include prescriber attestation or clinical records supporting treatment failure, resistance, optimized background therapy, and response, as applicable.
    Denial Risk

    Non-Covered Indications

    Do not submit Sunlenca for indications that are not recommended for approval under this policy.

    • Pre-exposure prophylaxis (PrEP) for HIV is not recommended; Sunlenca is not approved for this indication.
    • Use in HIV treatment-naïve patients is not recommended; Sunlenca is not approved for this indication.
    • Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria.
    Denial Risk

    Failure to Meet Initial Criteria

    Initial therapy is not approved unless every initial-therapy criterion is documented. Requests fail the initial criteria when the patient is younger than 18, is not failing the current HIV antiretroviral regimen, lacks the required resistance, will not use an optimized antiviral background regimen with one or more other antiretroviral agents, or lacks the required HIV-specialist prescribing or consultation.

    • Initial therapy, when approved, is authorized for 6 months.
    • The resistance requirement is two or more agents from at least three antiviral classes.
    Denial Risk

    Failure to Meet Continuation Criteria

    Continuation therapy is not approved unless both continuation criteria are documented. Deny or do not extend the request when the patient will not continue Sunlenca with an optimized antiviral background regimen or when the prescriber cannot document response to a Sunlenca-containing regimen.

    • Continuation therapy, when approved, is authorized for 1 year.
    • Response may be shown by HIV RNA < 50 copies/mm³, an HIV-1 RNA reduction of at least 0.5 log10 from baseline viral load, or improvement or stabilization of the CD4 T-cell count.
    Note

    Nonstandard Dosing

    Approve the established regimen of 927 mg subcutaneously once initially, followed by 927 mg subcutaneously every 6 months, with an allowance of ±2 weeks from the date of the last injection. Requests for dosing outside this schedule require case-by-case review.

    • Medical Director or Pharmacist review is required for nonstandard dosing.